BIOCRYST PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Debt Securities, Available-for-sale, Amortized Cost of $215.13 million as of 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2022-11-04
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost $215.13M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $145.16M.
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $47.92M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $9.99M; Debt Securities, Available-for-sale, Amortized Cost as first filed $9.99K.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2022-09-30 | $215.13M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $145.16M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $47.92M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $9.99M 10-Q · filed 2022-11-04 | $9.99K 10-K · filed 2022-02-28 |
| 2021-09-30 | $28.21M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $8.11M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $13.43M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $28.21M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $49.79M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $15.93M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $11.07M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $21.90M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $38.22M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $61.78M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $84.08M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $99.97M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $96.87M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $87.47M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $89.24M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $105.24M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |